title

Highlights of the European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Projects In Knowledge, Inc

1
Followers
0
Plays
Highlights of the European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Highlights of the European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Highlights of the European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Projects In Knowledge, Inc

1
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

This audio podcast reports on some of the most important new MS research presented at the ECTRIMS annual meeting, held October 13-16, 2010, in Gothenburg, Sweden. Listen as James D. Bowen, MD, talks about new findings that enhance understanding of MS pathophysiology, testing, neuroregeneration, and cognition. Fred D. Lublin, MD, reviews presentations on emerging and current MS therapies.

Latest Episodes

Update on Current MS Therapies - Part 2

Dr. Lublin discusses new data on other existing MS therapies: interferon beta, natalizumab, mitoxantrone, and fampridine.

8 MIN2010 OCT 28
Comments
Update on Current MS Therapies - Part 2

Update on Current MS Therapies - Part 1

Dr. Lublin discusses new data on existing MS therapies: glatiramer acetate and fingolimod, as well as the addition of statins to interferon beta-1a.

6 MIN2010 OCT 28
Comments
Update on Current MS Therapies - Part 1

Update on Emerging MS Therapies - Part 2

Dr. Lublin describes the latest data presented at ECTRIMS on additional emerging MS therapies (firategrast, cladribine, alemtuzumab, daclizumab, laquinimod, BG00012).

9 MIN2010 OCT 28
Comments
Update on Emerging MS Therapies - Part 2

Update on Emerging MS Therapies - Part 1

Dr. Lublin describes the latest data on some of the emerging MS therapies now in late-stage clinical trials (teriflunomide, ocrelizumab and ofatumumab), presented on ECTRIMS.

8 MIN2010 OCT 28
Comments
Update on Emerging MS Therapies - Part 1

Testing, Neuroregeneration, and Cognition

In this next section of the podcast, Dr. Bowen looks at the extent to which new data at ECTRIMS answer some important questions about MS testing, neuroregeneration, and cognitive impairment.

12 MIN2010 OCT 28
Comments
Testing, Neuroregeneration, and Cognition

MS Pathophysiology: Immunology and Genetics

Dr. Bowen discusses ECTRIMS presentations on lesser-known components of the immune system that contribute to the disease. He also discusses data on genetic causes of MS.

12 MIN2010 OCT 28
Comments
MS Pathophysiology: Immunology and Genetics
the END

Latest Episodes

Update on Current MS Therapies - Part 2

Dr. Lublin discusses new data on other existing MS therapies: interferon beta, natalizumab, mitoxantrone, and fampridine.

8 MIN2010 OCT 28
Comments
Update on Current MS Therapies - Part 2

Update on Current MS Therapies - Part 1

Dr. Lublin discusses new data on existing MS therapies: glatiramer acetate and fingolimod, as well as the addition of statins to interferon beta-1a.

6 MIN2010 OCT 28
Comments
Update on Current MS Therapies - Part 1

Update on Emerging MS Therapies - Part 2

Dr. Lublin describes the latest data presented at ECTRIMS on additional emerging MS therapies (firategrast, cladribine, alemtuzumab, daclizumab, laquinimod, BG00012).

9 MIN2010 OCT 28
Comments
Update on Emerging MS Therapies - Part 2

Update on Emerging MS Therapies - Part 1

Dr. Lublin describes the latest data on some of the emerging MS therapies now in late-stage clinical trials (teriflunomide, ocrelizumab and ofatumumab), presented on ECTRIMS.

8 MIN2010 OCT 28
Comments
Update on Emerging MS Therapies - Part 1

Testing, Neuroregeneration, and Cognition

In this next section of the podcast, Dr. Bowen looks at the extent to which new data at ECTRIMS answer some important questions about MS testing, neuroregeneration, and cognitive impairment.

12 MIN2010 OCT 28
Comments
Testing, Neuroregeneration, and Cognition

MS Pathophysiology: Immunology and Genetics

Dr. Bowen discusses ECTRIMS presentations on lesser-known components of the immune system that contribute to the disease. He also discusses data on genetic causes of MS.

12 MIN2010 OCT 28
Comments
MS Pathophysiology: Immunology and Genetics
the END